8-K: Milestone Pharma Q1 2026 Results: CARDAMYST Gains Traction

Milestone Pharmaceuticals reported Q1 2026 results, highlighting early sales traction for CARDAMYST, securing national formulary coverage, and initiating a Phase 3 trial for AFib-RVR, supported by a strong cash position.

Summary

• Milestone Pharmaceuticals announced its first quarter 2026 financial results and provided corporate updates.
• The company's product, CARDAMYST (etripamil) nasal spray, launched in mid-February 2026 for paroxysmal supraventricular tachycardia (PSVT), has seen initial positive reception with approximately 600 scripts filled for 560 patients through April.
• Over 400 unique prescribers have initiated treatment with CARDAMYST, and it now has coverage for over 25% of commercially insured lives in the U.S., including placement on Express Scripts national formularies as of March 27, 2026.
• The Phase 3 registration trial for etripamil in Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) has been initiated, with patient enrollment expected to begin in the second half of 2026.
• Milestone Pharmaceuticals ended the quarter with $184.2 million in cash, cash equivalents, and short-term investments, providing an expected runway into the second half of 2027.
• European regulatory review for etripamil nasal spray (TACHYMIST) is ongoing, with a decision expected in the first half of 2027.
• Everest Medicines acquired rights for CARDAMYST in Greater China, with the New Drug Application (NDA) accepted by China's NMPA in January 2025.
• Net loss for the first quarter of 2026 was $26.1 million, or $0.20 per share, compared to a net loss of $20.8 million, or $0.31 per share, in the prior year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with encouraging early commercial traction for CARDAMYST and progress in clinical development, balanced by increasing operating expenses and a continued net loss.

Positives

• CARDAMYST launch is gaining traction with positive initial healthcare professional reaction and early breadth of unique prescribers.
• Secured national formulary coverage with Express Scripts, enhancing patient access and affordability.
• Over 25% of commercially insured lives in the U.S. now have coverage for CARDAMYST.
• Initiated Phase 3 registration trial for etripamil in AFib-RVR, a significant step for expanded development.
• Strong balance sheet with $184.2 million in cash, providing runway into H2 2027.
• European Marketing Authorization Application (MAA) for etripamil accepted for review by the EMA.
• Everest Medicines acquired rights for CARDAMYST in Greater China, with NDA accepted by NMPA.
• Clinical data presented at major conferences (PCNA, ACC, Stanford BioDesign) supporting CARDAMYST's profile and potential benefits.

Negatives

• Net loss for Q1 2026 was $26.1 million, an increase from the prior year's net loss of $20.8 million.
• Commercial expenses increased significantly to $15.8 million in Q1 2026 from $10.4 million in Q1 2025 due to the CARDAMYST launch.
• Product revenue for Q1 2026 was only $0.2 million, indicating early stage commercialization.
• Net loss per share increased to $0.20 in Q1 2026 from $0.31 in Q1 2025, despite higher share count.

Risks

• Potential for delays in European regulatory approval (expected first half of 2027).
• Uncertainty regarding the outcomes of future interactions with regulatory bodies like the EMA.
• Risks associated with the complexity of cleaning, verifying, and analyzing clinical trial data.
• The possibility that clinical trials may not validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including inflation, tariffs, conflicts, and financial market fluctuations.
• Risks related to pandemics and public health emergencies.
• Sufficiency of capital resources and the ability to raise additional capital in the current economic climate.
• Potential for serious side effects of CARDAMYST, including fainting, dizziness, and cardiovascular effects.

Future Outlook

The company expects its cash reserves to fund operating expenses and capital expenditures into the second half of 2027, including costs associated with the initiation of the Phase 3 trial in AFib-RVR. A European decision on approval for etripamil nasal spray is expected by the first half of 2027. Patient enrollment for the AFib-RVR Phase 3 trial is expected to begin in the second half of 2026.

Management Comments

• "We're excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia, or PSVT. Healthcare professionals initial reaction to the product is positive and we are very encouraged by the early breadth of unique prescribers writing for their patients."
• "Gaining Express Scripts national formulary coverage in March reflects meaningful early payor adoption, highlighting the value CARDAMYST offers to insurers."
• "We are also observing clinician enthusiasm for expanded development of etripamil in patients with AFib-RVR, as we have now kicked off our Phase 3 pivotal trial and are actively engaging potential clinical trial sites."

Industry Context

StockSavvy.ai notes that Milestone Pharmaceuticals is navigating the competitive cardiovascular medicine market with its novel nasal spray, CARDAMYST. The company's progress in securing payor coverage and initiating new clinical trials aligns with industry trends of seeking innovative delivery methods and expanding indications for existing therapies to address unmet patient needs.

Comparison to Industry Standards

• The commercialization strategy for CARDAMYST, involving a dedicated sales force targeting specialists, is a standard approach for specialty pharmaceutical launches.
• The initiation of a Phase 3 trial for AFib-RVR follows a common pathway for expanding drug indications, leveraging existing safety and efficacy data.
• The company's cash runway of over 18 months is generally considered adequate for a commercial-stage biopharmaceutical company, though it is subject to the significant expenses of ongoing clinical trials and commercialization.

Stakeholder Impact

• Shareholders: The filing indicates progress in commercialization and clinical development, which could positively impact future share value, but also shows an increased net loss and commercial expenses.
• Patients: CARDAMYST is becoming more accessible through payor coverage, offering a new treatment option for PSVT patients.
• Healthcare Providers: Initial reception to CARDAMYST is positive, suggesting a potentially valuable new tool for managing PSVT.
• Insurers: Express Scripts' inclusion of CARDAMYST on its national formulary indicates a perceived value proposition for managing costs and patient outcomes.

Next Steps

• Begin patient enrollment in the AFib-RVR Phase 3 trial in H2 2026.
• Await European decision on etripamil MAA in H1 2027.
• Continue commercialization efforts for CARDAMYST in the U.S.
• Monitor progress of CARDAMYST development and commercialization in Greater China.

Key Dates

Recommendation

The company shows positive early signs of commercial traction for CARDAMYST and progress in its pipeline with the initiation of the AFib-RVR Phase 3 trial. However, the increased net loss and significant commercial expenses, coupled with the long lead time for European approval and ongoing clinical trial data needs, warrant a cautious 'hold' stance until further commercial uptake and clinical data become available.

Keywords

Milestone Pharmaceuticals, CARDAMYST, etripamil, PSVT, AFib-RVR, Q1 2026, financial results, biopharmaceutical